Mission

Bio-Converts mission is to develop the preferred treatment for oral leukoplakia. Our innovative therapeutic agent, QR-2, uses a novel drug delivery technology, that enables more precise, effective and efficient treatment.

Vision

Bio-Converts visions is to revolutionize the treatment of oral leukoplakia, with our unique QR-2 patch. Aimed at minimizing or remove oral leukoplakia lesions, that further reduces the risk of patients developing oral cancer from it.

Background

Oral leukoplakia is a potentially cancerous white patch or plaque in the mouth, strongly linked to smoking. The edges of the lesion are typically abrupt and the lesion changes. Oral leukoplakia also has dysplasia which highlights the severity of the disorder and is a marker of disease progression. Dysplasia is abnormal cell growth, a precancerous condition more serious than normal cell overgrowth (hyperplasia). In adults, precancerous dysplasia may not always turn into cancer, but there's a risk it could.Bio-Convert have identified a novel drug delivery technology, that we believe holds significant potential to become the preferred future treatment of oral leukoplakia (OL) using our unique patch, QR-2. The patch is applied directly to the lesions in the mouth. The treatment is intended to reduce/remove the OL lesions, and it will facilitate surgical procedure and improve, and reduce the malign conversion rate, lowering the risk of them turning into cancer.

Bio-Convert’s process:

Enter into contracts with reputable partners possessing the appropriate technology to conduct clinical trials.
Formulation development.
Conduct pre-clinical tests.
Submit global patent applications.
Commence the initial clinical Proof of Concept (POC) study.
The anticipated timeline for advancing the development project is approx. 24 months, starting in November 2023.

Strategy

Bio-Converts developmental strategy consists of: Using a proprietary patch formulation consisting of three layers with long patent life. Imiquimod will be used as active ingredient and is administered on daily for 12 weeks. Enroll patients with moderate to severe dysplasia in the study. Once the prototype and final formulation are tested in a phase IA, including local tolerability, the product is ready, and evaluating for tolerability and preliminary efficacy will be initiated.

Management Team

Mr. Wehnert has over 30 years in the pharmaceutical industry, specializing in discovering and developing new molecules for central nervous system disease treatment. A trained pharmacologist, he’s authored 25 scientific papers in prestigious international journals. Currently, as Initiator Pharma’s Senior VP for Research and Development, he advises private equity syndicates and owns Decision Insights.

During his 25-year tenure as Senior VP at Lundbeck, Allan led drug development from pre-clinical stages to NDA/EMA approval. He played a key role in bringing 6 products to market and overseeing over 75 due diligence processes, along with more than 7 asset and company acquisitions.

Board of Directors

Peter Severing - Chairman

Mr. Severin brings over 25 years life sciences and sales experience to Orocidins Board. Mr. Severin is currently the Founder and CEO of Severin Partners, a sales and communications consulting company focusing on the healthcare industries. He also serves as Chairman of the U.S.-based Life Sciences holding company, Nordicus Partners Corporation. Prior to founding Severin Partners, Peter held positions as Head of Sales of Novartis AG, Sales Manager at AstraZeneca Pharmaceuticals and as Sales Manager of GSK Plc (formerly GlaxoSmithKline Plc).

Henrik Rouf - Member

Mr. Rouf has 30 years of experience in the global finance markets, working as an international financier, merchant banker and fund manager, respectively. Mr. Rouf advises and finances companies in many industries, including (though not limited to) software, semiconductors, blockchain, healthcare, medical devices, biotechnology, restaurant chains, apparel, cannabis, clean tech and advertising. Mr. Rouf has since 2004 been the President of PacificWave Partners Inc., a California-based merchant bank, and is also currently the CEO of the U.S. based Life Sciences holding company, Nordicus Partners Corporation. By being located and working in the United States for more than 30 years, Mr. Rouf has a vast network and extensive ties to especially the U.S., but also to Europe and Asia.

Henrik Keller - Member

Mr. Keller has more than four decades of experience in the corporate sector, in which he has a proven track record of delivering excellent performances. Mr. Keller possesses a unique set of strategical, managerial and sales capabilities, which has been key in the documented success he has delivered to the companies he has been, and are currently involved with, serving in various positions as Owner, General Manager, Sales Manager, Consultant/Advisor, Board Member, etc. Through his professional career, Mr. Keller has established a network which spans globally. Mr. Keller is currently the owner of the consultancy firm, HK-Consult, which advises companies within sales, marketing, customer service, partner search, strategy, etc. Mr. Keller further serves as the European representative for Blake Medical (CA); Scandinavian representative for Medical Spare Parts BV (NE). Mr. Keller also serves as Board Member for the U.S. based Life Sciences holding company, Nordicus Partners Corporation. From 2009 to 2012 he served as Board Member, Consultive Director and Partner at Athene Healthcare A/S; From 1998 to 2008 Mr. Keller was the General Manager at Huntleigh Healthcare A/S and General Manager for the Nordic Region at ArjoHuntleigh, after Huntleigh Healthcare A/S had a very successful merger with the Arjo Nordic companies.

About Us